United Therapeutics Q2 EPS $5.24 Beats $4.41 Estimate, Sales $596.50M Beat $532.33M Estimate
Portfolio Pulse from Benzinga Newsdesk
United Therapeutics (NASDAQ:UTHR) reported Q2 earnings of $5.24 per share, beating the analyst consensus estimate of $4.41 by 18.82%. This is a 117.43% increase from the same period last year. The company also reported quarterly sales of $596.50 million, beating the analyst consensus estimate of $532.33 million by 12.05%, a 27.76% increase from last year.
August 04, 2023 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
United Therapeutics reported strong Q2 earnings and sales, significantly beating estimates and showing a substantial increase from the same period last year.
United Therapeutics reported Q2 earnings and sales that significantly beat analyst estimates, and showed a substantial increase from the same period last year. This strong performance is likely to have a positive impact on the company's stock price in the short term.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100